|
業務類別
|
Biotechnology |
|
業務概覽
|
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. |
| 公司地址
| 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005 |
| 電話號碼
| +1 415 798-8589 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.tempesttx.com |
| 員工數量
| 25 |
| Dr. Matthew Angel, PhD |
Director, President and Chief Executive Officer |
-- |
06/02/2026 |
| Dr. Samuel Whiting, M.D.,PhD |
Executive Vice President and Chief Medical Officer |
美元 481.75K |
31/12/2025 |
| Mr. Nicholas Maestas |
Chief Financial Officer, Head of Corporate Strategy and Corporate Secretary |
美元 365.55K |
31/12/2025 |
| Mr. Justin Trojanowski |
Corporate Controller, Treasurer and Principal Accounting Officer |
-- |
27/03/2025 |
|
|
| Ms. Christine A. Pellizzari |
Independent Director |
31/12/2025 |
| Mr. Michael G. Raab |
Director |
06/02/2026 |
| Mr. Stephen R. Brady |
Chairman of the Board |
06/02/2026 |
| Dr. Ronit Simantov, M.D. |
Independent Director |
31/12/2025 |
| Dr. Matthew Angel, PhD |
Director, President and Chief Executive Officer |
06/02/2026 |
|
|
|
|
